Brief: Bioarctic And Novartis Sign Option, Collaboration And License Agreement
26/08/2025 06:06
Aug 26 (Reuters) - BioArctic AB BIOAb.ST: BIOARCTIC AND NOVARTIS SIGN AN OPTION, COLLABORATION AND LICENSE AGREEMENT USING BRAINTRANSPORTER™ FOR AN UPFRONT PAYMENT OF USD 30 MILLION PLUS ADDITIONAL POTENTIAL MILESTONES AND ROYALTIES Source text: ID:nWkr3V7dJg Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln